Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly to Invest $1B in India to Expand Manufacturing Capacity | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly to Invest $1B in India to Expand Manufacturing Capacity

Aims to increase availability of key drugs for obesity, diabetes, Alzheimer's, cancer and autoimmune conditions.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Lilly expands manufacturing in India

Eli Lilly and Co. plans to invest more than $1 billion in India to expand manufacturing and supply through local drugmakers, as reported by Reuters. 

Lilly aims to increase availability of key drugs for obesity, diabetes, Alzheimer’s, cancer and autoimmune conditions, according to the company. The company launched its weight-loss drug Mounjaro in India this year and does not currently operate its own manufacturing facility in the country.

“We are making significant investments to increase manufacturing and medicine supply capacity around the world,” Patrik Jonsson, president of Lilly International, said, adding, India is a hub for capability building within its global network.

“Lilly is actively engaging with contract manufacturers in India,” the company told Reuters.

Lilly recently announced a $5 billion investment in a new facility in Virginia, part of a $27 billion expansion plan to build four new U.S. plants over the next five years.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics